SCHEMBL9604664

SCHEMBL9604664

CNCCCOCC(C)C

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR1B P28222 2/20 0.38
KISS1R Q969F8 1/20 0.34
EPHX1 P07099 1/20 0.33
KDM4E B2RXH2 3/20 0.33
ALDH1A1 P00352 2/20 0.33
NSD2 O96028 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
SPHK2 Q9NRA0 1/20 0.33
SPHK1 Q9NYA1 1/20 0.33
NAMPT P43490 1/20 0.32
HRH1 P35367 2/20 0.32
SLC6A4 P31645 1/20 0.32
LMNA P02545 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
HTR1D P28221 1/20 0.30
HSD17B10 Q99714 1/20 0.30
L3MBTL4 Q8NA19 1/20 0.30
L3MBTL3 Q96JM7 1/20 0.30
PLA2G2C Q5R387 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23560285 0.96 HTR1B (0.35) HTR1BKISS1REPHX1KDM4EALDH1A1
SCHEMBL23897093 0.93 EPHX1 (0.37) HTR1BKISS1REPHX1SPHK2SPHK1
SCHEMBL20648659 0.91 EPHX1 (0.41) HTR1BKISS1REPHX1SPHK2SPHK1
SCHEMBL9024417 0.85
Ammonia Solution, Strong SCHEMBL29051935 0.83 KDM4E (0.32) HTR1BKDM4ELMNATDP1HTR1D
SCHEMBL20127154 0.81 SPHK2 (0.33) KDM4EALDH1A1SPHK2SPHK1NAMPT
SCHEMBL23695892 0.81 MEN1 (0.38) HTR1BKDM4ELMNATDP1HTR1D
SCHEMBL22848852 0.81 MEN1 (0.38) HTR1BKDM4ELMNATDP1HTR1D
SCHEMBL20076246 0.81 MEN1 (0.38) HTR1BKDM4ELMNATDP1HTR1D
SCHEMBL14870333 0.80 HTR1B (0.34) HTR1BEPHX1KDM4EALDH1A1NSD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024148060-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2024-07-11 WO disclosed
WO-2023192586-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-10-05 WO disclosed
WO-2023192578-A1 PROTEIN DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-10-05 WO disclosed
WO-2023076161-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-05-04 WO disclosed
US-20230110180-A1 CDK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-13 US disclosed
WO-2023278759-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-01-05 WO disclosed
WO-2022147465-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-07-07 WO disclosed
WO-2022125790-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-06-16 WO disclosed
WO-2021127190-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-06-24 WO disclosed
WO-2021127278-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-06-24 WO disclosed
US-7563489-B2 piezoelectric ink jet printing; low jetting temperatures; curable epoxy-polyamide composite gellant and a reactive diluent; XEROX CORPORATION (US) 2009-07-21 US disclosed
US-7556844-B2 Radiation curable photochromic inks XEROX CORPORATION (US) 2009-07-07 US disclosed
US-7531582-B2 Radiation curable phase change inks containing curable epoxy-polyamide composite gellants XEROX CORPORATION (US) 2009-05-12 US disclosed
US-7459014-B2 Radiation curable inks containing curable gelator additives XEROX CORPORATION (US) 2008-12-02 US disclosed
US-20080122914-A1 RADIATION CURABLE PHASE CHANGE INKS CONTAINING CURABLE EPOXY-POLYAMIDE COMPOSITE GELLANTS XEROX CORPORATION (US) 2008-05-29 US disclosed
US-20070211110-A1 RADIATION CURABLE PHOTOCHROMIC INKS XEROX CORPORATION (US) 2007-09-13 US disclosed
US-20070120924-A1 Radiation curable phase change inks containing gellants XEROX CORPORATION (US) 2007-05-31 US disclosed
US-20070120921-A1 Radiation curable phase change inks containing curable epoxy-polyamide composite gellants XEROX CORPORATION (US) 2007-05-31 US disclosed
US-5219480-A ETHYLENE ALPHA-OLEFIN MANNICH BASE VISCOSITY INDEX IMPROVER/DISPERSANT ADDITIVES DERIVED FROM AMINO PHENOLS AND MONOSECONDARY AMINES EXXON CHEMICAL PATENTS INC. (US) 1993-06-15 US disclosed
EP-0357215-A1 Ethylene alpha-olefin mannich base viscosity index improver/dispersant additives EXXON CHEMICAL PATENTS INC. (US) 1990-03-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230110180-A1 CDK2 DEGRADERS AND USES THEREOF CDK2, CDK20, CDK1 HTR1B 3996/4885KISS1R 2423/4885EPHX1 2198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.